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We and others have previously identified a group of genes, dubbed “disallowed,”
whose expression is markedly lower in pancreatic islets than in other mammalian cell
types. Forced mis-expression of several members of this family leads to defective
insulin secretion, demonstrating the likely importance of disallowance for normal beta
cell function. Up to now, transcriptomic comparisons have been based solely on
data from whole islets. This raises the possibilities that (a) there may be important
differences in the degree of disallowance of family members between beta and other
either neuroendocrine cells; (b) beta (or alpha) cell disallowed genes may have gone
undetected. To address this issue, we survey here recent massive parallel sequencing
(RNA-Seq) datasets from purified mouse and human islet cells. Our analysis reveals
that the most strongly disallowed genes are similar in beta and alpha cells, with
11β-hydroxysteroid dehydrogenase (Hsd11b1) mRNA being essentially undetectable
in both cell types. The analysis also reveals that several genes involved in cellular
proliferation, including Yap1 and Igfbp4, and previously assumed to be disallowed in
both beta and alpha cells, are selectively repressed only in the beta cell. The latter
finding supports the view that beta cell growth is selectively restricted in adults, providing
a mechanism to avoid excessive insulin production and the risk of hypoglycaemia.
Approaches which increase the expression or activity of selected disallowed genes in
the beta cell may provide the basis for novel regenerative therapies in type 2 diabetes.
Keywords: Hsd11b1, glucocorticoids, islets of langerhans, beta cells, alpha cells, diabetes mellitus, disallowed
genes
INTRODUCTION
Pancreatic beta cells detect small fluctuations in circulating glucose levels by coupling oxidative
metabolism to the regulation of ATP-sensitive K+ channels, and consequently to Ca2+ influx
(Rutter et al., 2015). The loss or dysfunction of beta cells contributes to all forms of diabetes
mellitus, a disease affecting more than 400 m individuals worldwide1.
1http://www.idf.org
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Studies in the early 1990s (Sekine et al., 1994) revealed that two
“housekeeping” genes, LDHA and SLC16A1 (Monocarboxylate
transporter-1, MCT-1), which are abundant in essentially all
mammalian cell types and permit vigorous glycolytic flux during
anaerobosis, are expressed at vanishingly low levels in beta cells.
Subsequent studies by ourselves (Pullen et al., 2010; Pullen and
Rutter, 2013) and others (Thorrez et al., 2011; Lemaire et al.,
2016) have provided a list of ∼60 genes which are selectively
disallowed in these cells, of which there is general consensus on
a list of ∼11 genes (Pullen and Rutter, 2013). Re-expression of
Slc16a1 or Ldha (Zhao and Rutter, 1998; Ishihara et al., 1999;
Ainscow et al., 2000; Pullen et al., 2012) as well as the acyl-CoA
thioesterase, Acot7 (Martinez-Sanchez et al., 2016) in the beta cell
leads to defects in insulin secretion, suggesting that the silencing
of these genes in beta cells is likely to be functionally relevant.
Previous studies to identify islet disallowed genes have,
however, analyzed whole islet transcriptome data (Pullen et al.,
2010; Thorrez et al., 2011). Because islets are composed of
multiple cell types (Elayat et al., 1995), this has not given a clear
picture for any one cell type: the possibility consequently exists
that certain genes may be less “disallowed” in the less abundant
islet endocrine cells (notably alpha and delta) than in beta cells.
It has therefore been of interest to explore this question using
datasets recently made available from highly purified islet cell
types (Benner et al., 2014; Adriaenssens et al., 2016; DiGruccio
et al., 2016), as well as our own, previously unpublished data.
With this goal in mind, we have used a similar strategy to previous
analyses but taking advantage of the increased dynamic range
of RNA-Seq and the purified cell type datasets to reveal a more
detailed insight of genes disallowed alpha and beta cells.
While we confirm that many previously identified islet
disallowed genes are indeed disallowed in both alpha and beta
cells, we also reveal a number of genes which are expressed
at a far lower level in beta cells and whole islets. Strikingly,
11β-hydroxysteroid dehydrogenase (Hsd11b1) a critical enzyme
for the conversion of the inactive precursor of corticosterone,
11-dehydrocorticosterone (11-DHC) (Seckl and Walker, 2001), is
found to be remarkably weakly expressed in both beta and alpha
cells, as well as in delta cells. This suggests that previous findings
demonstrating actions of 11-DHC on insulin secretion (Davani
et al., 2000) may reflect a requirement for non-beta cells in the
activation of this molecule.
We also note that genes involved in cell proliferation (e.g.,
Yap1, Igfbp4) are more selectively inactivated in beta than alpha
cells. This is consistent with an evolutionarily driven mechanism
to suppress the proliferation of beta cells in adults and thus a risk
of life-threatening hypoglycaemia.
MATERIALS AND METHODS
Identification of Disallowed Genes in
Adult Mouse Tissues and Purified Cells
RNA-Seq datasets for a range of normal mouse tissues were
obtained from public repositories and our own data. These
included: 10 datasets for FACS-purified alpha cells from three
studies (Benner et al., 2014; Adriaenssens et al., 2016; DiGruccio
et al., 2016); 14 FACS-purified beta cell datasets from four
studies (Benner et al., 2014; Adriaenssens et al., 2016; DiGruccio
et al., 2016; E-MTAB-2266); and 15 islet datasets from our
own and other studies (Kone et al., 2014; GSE90531). Non-
islet tissue datasets covering brain, heart, kidney, liver, lung,
spleen, and thymus were included for comparison. Dispersed,
FACS-purified cells contain many differences to dissected tissues
including lack of blood and endothelial cells. To control for these
differences, eight datasets of FACS-purified hepatocytes were
included. Islet, alpha, and beta cell data were derived from data
series with GEO or ArrayExpress accession numbers: GSE54973,
E-MTAB-2266, GSE80673, GSE76017, GSE90531, and E-MTAB-
2791. Non-islet tissue and cell data were derived from data series
with accession numbers: GSE36025, GSE74747, GSE65207, and
GSE68806.
Where data were in paired-end format, the second read was
discarded for each fragment to allow a more direct comparison
with the single-ended data. Reads were mapped to the mouse
genome (GRCm38) using HiSat2 (Kim et al., 2015) and annotated
transcripts quantified with featureCounts (Liao et al., 2014).
Differential expression analysis was performed using DESeq2
(Love et al., 2014). Alpha cell, beta cell, and islet data were
then subjected to pairwise comparisons against each non-
islet tissue and cell type. There is an acknowledged problem
that detecting differential expression by significance alone can
result in the selection of genes with small but consistent
changes which are of questionable biological significance while
excluding larger but more variable changes. In an attempt to
overcome this, the fold-change and significance were combined
into a single metric, the pi-value (Xiao et al., 2014). The
pi-values for each pairwise comparison were combined where
the direction of change was consistent (e.g., genes whose
expression was higher or lower in beta cells than all other
non-islet datasets) by taking the pi-value closest to zero (i.e.,
least combined significance and fold-change) for each gene.
Genes were ranked by pi-value allowing the most consistently
under- and over-expressed genes to be identified at both ends
of the resulting list. Since the number of datasets included
for alpha cells, beta cells, and islets was not consistent,
this is likely to have affected the number of differentially
expressed genes detected in each case. For this reason, we
have concentrated on comparing the ‘most disallowed’ genes
at the top of the ranked gene lists in these cell types
rather than using a significance/fold-change threshold to define
disallowance.
Cluster Analysis
The top 50 disallowed genes from alpha and beta cells
were combined and hierarchical clustering performed on the
basis of fold-change in gene expression in each tissue/cell
type relative to islets. Weighted gene co-expression network
analysis (WGCNA) was also performed on variance-stabilizing
transformed count data exported from DESeq2 (Langfelder and
Horvath, 2008). Functional characterization of gene lists using
Gene Ontology (GO) Biological Process and PANTHER protein
class was performed through the PANTHER website (Mi et al.,
2017).
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Developmental Regulation of Disallowed
Genes
Transcriptomes of FACS-purified beta cells at different peri- and
post-natal maturation stages were generated using the mIns1-
H2b-mCherry reporter line (Benner et al., 2014) (Jax # 028589).
Breeders homozygous for mIns1-H2b-mCherry were crossed
to wild-type C57bl6 mates to ensure offspring were uniformly
hemizygous for the mCherry reporter. Islets from single litters (a
mix of male and female is expected) were pooled for each sample
to obtain sufficient material. Pooled islets were dissociated, sorted
and collect in Trizol for RNA isolation and library construction.
Each time point was collected in the morning and FACS-sorted
at the conclusion of the islet prep the same day. Each time point
was done in duplicate or triplicate. Data are deposited under GEO
accession number GSE88779.
Gene Expression Association with Type 2
Diabetes Status in Human Islets
To investigate whether the expression of the human orthologues
of these genes are altered during the progression of type 2
diabetes, we exploited RNA-Seq data on pancreatic islets isolated
from 89 human donors (Fadista et al., 2014). Gene expression was
quantified using the pipeline described above using the GRCh37
genome, and differential expression relative to diabetes status
determined by DESeq2. The top 20 beta cell disallowed genes
were investigated for a significant association between expression
and diabetes status.
RESULTS
Once the datasets were assembled, the analysis yielded the genes
which were most enriched and most disallowed in alpha and
beta cells (Figure 1A). The results were ranked by the pi-value
which combined both the log fold change and adjusted p-value
into a single metric. It should be noted that our analysis is based
on pairwise comparisons between the islet cell type and each
of the non-islet tissues, and the smallest pi-value from each of
these comparisons is used for each gene. Since this analysis is
based on the smallest pi-value from comparisons with each other
tissue it identifies genes which are consistently over- or under-
represented in a particular cell type, rather than those with the
largest median difference.
The similarity between the 20 genes most consistently
repressed in alpha and beta cells, relative to non-islet tissues,
is notable. Thus, 11 of these genes are common between the
two lists. Functional classification of the top 50 disallowed genes
in each cell type again revealed the similarity between the two
lists, with ‘cellular process,’ ‘metabolic process’ and ‘biological
regulation’ being the top three GO Biological Process terms in
both lists (Figure 1B).
To study the similarities between the lists for the two
cell types, the top 50 disallowed genes for each were merged
and clustered on the basis of differential expression across all
cell/tissue types (Figure 2A). While 27 of these genes were shared
between the two cell types, the differences between the lists were
FIGURE 1 | (A) Ranked list of the top 20 most disallowed (selectively
down-regulated) genes in pancreatic alpha and beta cells, with overlap
between the two lists highlighted by lines. (B) Functional annotation of the top
50 disallowed gene in each cell type on the basis of Gene Ontology (GO)
Biological Process.
equally interesting. One cluster contained five genes which were
disallowed selectively in beta cells, but not alpha cells (Fam13a,
Acot1, Ablim3, Chn2, Rxrg). The genes in this cluster exhibit
lower expression in purified beta cells than in whole islets, and
higher expression in alpha cells. A smaller cluster of three genes
(Pcsk5, Yap1, Colex12) has a similar expression pattern, whereas
the majority of the other beta cell disallowed genes also had low
expression in alpha cells.
We sought to further investigate the differences in selectively
repressed genes between alpha and beta cells using WGCNA
of normalized count data from all the tissue/cell types. This
approach identified a single module, containing 50 genes, which
was significantly down-regulated in beta cells (p = 3 × 10−17)
and islets (p = 2 × 10−12) but not alpha cells (p = 0.3;
Supplementary Table S1). This module included most of the
genes in the clusters described above. Searching for enrichment of
GO terms revealed the enzyme-linked receptor signaling pathway
(p = 0.023). This observation provides insights into possible
differences in the proliferative capacity of alpha and beta cells.
Functional classification of the genes within this module
showed that many were associated with metabolic processes
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(Figure 2B). A preponderance of nucleic acid binding,
transcription factor and signaling molecules among the
protein classes (Figure 2C) also indicates that selective silencing
of this module in beta cells may contribute to the regulation of
beta cell identity.
Figure 3 shows the intersection of data between previous
analyses and the current analysis of islet disallowed genes (A)
and between the different cell types and islets (B) and reveals that
while there is considerable overlap between these datasets, we also
noted genes not previously classed as disallowed.
We next compared the levels of expression of five of the
genes disallowed in alpha and/or beta cells (Figure 4). Of these,
the most dramatically disallowed is Hsd11b1 with nearly a
1000-fold gradient existing between expression in brain versus
purified alpha or beta cells, where mRNA levels were at or
below the level of detection (<10 normalized counts). Relatively
abundant expression in other islet cell types presumably explains
its considerably higher expression in isolated islets.
Interestingly, both Igfbp4 and Yap1 are approximately one
order of magnitude more highly expressed in alpha than beta
cells, indicating that the disallowance of these genes is likely to be
more relevant to the beta cell phenotype than that of alpha cells.
Next, we sought to determine the time points at which
members of the family of disallowed genes become inactivated
in beta cells through analyzing RNA-Seq data from purified beta
cells at various developmental stages (Figure 5). Strikingly, of
those sampled, the majority were already very weakly expressed
by embryonic day 18 (E18). Gas1 provided an exception in that
mRNA levels encoding this enzyme declined (albeit from low
levels) between E18 and P7.
Finally, we investigated whether increased expression of any of
these disallowed genes is associated with type 2 diabetes (Table 1).
Of the top 20 beta cell disallowed genes, increased expression of
six was associated with diabetes with an adjusted p-value < 0.1,
with IGF1 showing the most significant association.
DISCUSSION
Comparison of Current Methodology to
Previous Studies
The approach taken in this analysis differs from previous analyses
in a number of ways, in addition to the use of data from purified
cell types rather than isolated pancreatic islets. The largest
difference is the use of RNA-Seq rather than microarray data. The
principle advantages of RNA-Seq are the higher dynamic range
(Zhao et al., 2014) and the fact that quantification is based on
the whole length of the gene rather than the limited coverage of
probesets. However, in addition to using a different platform, the
analysis is also different in the current study.
Previous analyses have concentrated either on the statistical
significance of the difference (Thorrez et al., 2011), or on a
fold-change threshold (Pullen et al., 2010). The present analysis
combined both measures into a pi-value with the aim of
capturing both highly significant (consistent) changes of a smaller
magnitude and less significant (more variable) changes with a
greater magnitude. Furthermore, ranking genes by this combined
score is arguably more biologically meaningful than ranking
by either significance or fold-change alone. We note, however,
that demonstration of the relative strengths of this approach
versus others will require future biological assessments, e.g.,
overexpression of candidate genes (Pullen et al., 2012; Martinez-
Sanchez et al., 2016).
It is possible to assess the combined effect of these changes
by comparing the current analysis of whole islets with previous
analyses (Figure 3). The overlap between the top 50 islet
disallowed genes from this study and the lists of 39 and 40
genes from the Pullen et al. (2010) and Thorrez et al. (2011)
papers, respectively, is just two genes: Slc16a1 and Igfbp4. This
is reassuring since there is strong evidence that Slc16a1 is
specifically silenced in islets (Zhao et al., 2001), and that mis-
expression of this gene in human (Otonkoski et al., 2007)
and mouse (Pullen et al., 2012) beta cells causes inappropriate
stimulation of insulin secretion in response to pyruvate.
The current list also contains six genes which overlap with
the Pullen list but none with the Thorrez list. It is interesting to
note that five genes common to both the Pullen and Thorrez lists
are not included in the current islet list: Ldha, Cd302, Pdgfra,
Cxcl12, and Oat. Of these, both Ldha and Oat are within the
top 100 of the current list, so while their rank may be altered
slightly in the current analysis, there is still strong evidence for
their categorization as islet disallowed genes.
Pdgfra is an interesting disallowed gene because there is
evidence that a gradual lowering in its expression plays a role
in the age-dependent decline in beta cell proliferative capacity
(Chen H. et al., 2011). However, Pdgfra also displays relatively
low expression in liver and strikingly low expression in purified
hepatocytes. While this does not detract from the important role
of Pdgfra repression in beta cells, it does exclude it from our strict
definition of islet disallowed genes.
Alpha and Beta Cell Disallowed Genes
The main aim of this study was to identify novel disallowed
genes in alpha and beta cells, particularly those whose low
expression may have been masked by expression in other islet
cell types. When searching for genes specifically expressed in
a particular cell type, low levels of contamination with other
cell types have relatively little impact because they are unlikely
to lead to false negatives and will only occasionally lead to
false positives if the level of contamination is high. However,
contamination is likely to be more of an issue when searching for
cells specifically repressed in one cell type, since the expression
in the contaminating cells will be easily detectable over the low
background.
A striking feature of the lists of alpha and beta cell disallowed
genes is their remarkable similarity. In contrast to enriched genes,
which contain few similarities between cell types (Xin et al.,
2016), the disallowed genes were notably similar (Figure 1).
Looking at this aspect of cell identity suggests that alpha and beta
cells are more similar than the impression given by looking at
highly expressed genes, and is presumably an important aspect
of reprogramming from an alpha cell to a beta fate (and vice
versa) in some circumstances (Collombat et al., 2009; Thorel
et al., 2010).
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FIGURE 2 | (A) Hierarchical cluster analysis of a combined list of the top 50 disallowed genes from both alpha and beta cells. Membership of the top 50 alpha
and/or beta cell list is indicated by the gray bars on the right. Heatmap shading denotes fold-change in gene expression relative to islets, with blue representing up-
and red down-regulation. A cluster of 50 genes selectively repressed in beta but not alpha cells was identified by weighted gene co-expression network analysis
(WGCNA), and genes were functionally annotated on the basis of Biological Process (B) and Protein Class (C).
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FIGURE 3 | Comparison of disallowed gene expression in isolated mouse islet cells versus intact islets. Venn diagram showing the overlap between the
top 50 disallowed islet genes from this study (Yellow) with lists from previous studies by Pullen et al. (2010; Red) and Thorrez et al. (2011; Green) (A). The overlap
between the top 50 disallowed genes from islets (Green), alpha (Yellow), and beta cells (Red) is also shown (B).
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FIGURE 4 | Expression of selected disallowed genes across different
mouse tissues. Gene expression is presented in normalized read counts per
gene along with mean expression level across all tissues are shown for some
of the genes highlighted in this study.
FIGURE 5 | Changes in disallowed gene expression during post-natal
development. Expression of disallowed genes in purified insulin-positive cells
from pre- and post-natal mice is shown along with the expression of
glucokinase (Gck) for comparison. The six genes exhibiting the highest
expression during this period are shown (A), and Gas1 is also shown as one of
the few genes exhibiting a consistent down-regulation during this period (B).
There is also considerable overlap between alpha cell, beta
cell, and islet disallowed gene lists (Figure 3B), which includes
several previously identified islet disallowed genes: Slc16a1,
Fxyd1, Ndfg2, Gas1. However, it is particularly interesting to
consider a few examples of disallowed genes which are either
newly identified or ranked more highly in the current analysis of
purified cells.
Hsd11b1 is the highest ranked beta cell disallowed gene, and
second on the alpha cell list. While Hsd11b1 is also included
on the islet disallowed list, the reason for its high rank in the
purified cell types becomes apparent from a plot of its expression
profile (Figure 4). Although the islet expression level is over an
order of magnitude lower than any non-islet tissue, expression in
alpha and beta cells is a further order of magnitude below this.
Indeed, since the DESeq2 tool used in this analysis adds 0.5 to
all normalized counts it can be seen from Figure 4 that no reads
mapped to Hsd11b1 in two alpha cell, and three beta cell samples,
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TABLE 1 | The association of expression of beta cell disallowed genes in
human islets with type 2 diabetes status.
Gene baseMean LFC AdjP
IGF1 5.87 0.957 0.0185
MGLL 442 0.738 0.0357
CXCL12 500 0.774 0.0448
IGFBP4 4241 0.566 0.0786
SMOC2 57 0.718 0.0932
SLC16A1 430 0.509 0.0959
RNA-Seq data from Fadista et al. (2014) were analyzed relative to diabetes status
determined by HbA1c levels. The six genes showing associations with adjusted
p < 0.1 are reported here, and all have positive log fold change (LFC) indicating
that type 2 diabetes is associated with increased expression.
and fewer than 10 normalized counts were detected in any alpha
or beta cell sample. This level would normally be considered
below the threshold of detectable expression, i.e., the gene is
essentially silent in both cell types. Of note, although expression
of Hsd11b1 is still very low in islets, the levels detected in the
intact micro-organ are much higher than in purified alpha or beta
cells. We find no evidence of expression in delta cells (DiGruccio
et al., 2016) so this most likely reflects significant Hsd11b1
expression in other non-endocrine islet cell types (endothelial,
pericytes, etc.).
HSD11B1 encodes an enzyme which converts inert
cortisone into active cortisol (or 11-dehydroxycorticosterone to
corticosterone in rodents), thus regulating local glucocorticoid
action in metabolically active tissues (Seckl and Walker, 2001).
Glucocorticoids have long been associated with adverse metabolic
effects, including increased insulin resistance. Indeed, steroid-
induced diabetes is a significant complication of glucocorticoid
therapy (Hwang and Weiss, 2014). Hsd11b1 is reportedly the
major regulator of tissue-specific glucocorticoid effects (Morgan
et al., 2014). Overexpression of Hsd11b1 in either liver (Paterson
et al., 2004) or adipose tissue (Masuzaki et al., 2003) renders mice
insulin resistant, conversely knockout of this gene protects mice
from glucocorticoid-induced insulin resistance (Morgan et al.,
2014). In humans HSD11B1 hyperexpression has been associated
with abnormal glucose metabolism and obesity in several studies
(Nascimento et al., 2015). Whereas the diabetogenic effects of
glucocorticoids have mainly been attributed to increased insulin
resistance, there is some evidence that they involve beta cells
directly.
Many reports of the effects of glucocorticoids on beta
cells have highlighted inhibitory roles such as suppression
of both insulin secretion (Chen F. et al., 2011) and cellular
proliferation (Colvin et al., 2013) by the synthetic glucocorticoid,
dexamethasone. Indeed, it would be adaptive for endocrine
cells not to generate cortisol/corticosterone locally as this would
preserve their ability to respond to circulating cortisol [derived
from hypothalamus pituitary adrenal (HPA) axis activity]
without any interference of local 11 HSD activity. After all,
GCs are the functional antagonist of insulin and the two are
cross-regulatory.
We have previously shown (Huising et al., 2011) that acute
dexamethasone stimulation inhibits beta cell GLP1 receptor
expression in a glucocorticoid receptor-dependent manner,
confirming earlier findings. It is interesting to note that acute
restraint stress elicited similar effects in mouse islets after
3 h, and these had normalized after 12 h. This suggests that
acute stress transiently attenuates the sensitivity of beta cells to
incretins by suppressing the expression of its receptors in order
to facilitate the hyperglycemia induced by glucocorticoids. This
acute, transient repression of insulin release by glucocorticoids is,
in the above context, adaptive. However, in metabolic syndrome,
the same mechanisms may rapidly become maladaptive.
However, other studies suggest that glucocorticoids may
stimulate insulin secretion and/or beta cell survival in certain
circumstances. For example, in vitro pre-treatment with low
concentrations (200 nM) of corticosterone for 18 h increased
glucose-stimulated insulin secretion from isolated islets (Hult
et al., 2009). Dex also reportedly increased glucose-stimulated
insulin secretion in islets isolated from rats that were treated
in vivo with Dex (Rafacho et al., 2010), although it is
difficult to dissociate effects on the islet from other systemic
actions. Glucocorticoid pre-treatment also improved the function
of transplanted human islets (Lund et al., 2008). Finally,
overexpression of Hsd11b1 is reported to offer some protection
against high-fat diet-induced glucose intolerance, through
increasing both islet mass and function (Turban et al., 2012).
Together, these findings suggest that the anti-inflammatory
action of glucocorticoids may enhance beta cell function
under certain conditions, although prolonged and/or high level
treatment may interfere with both beta cell function and
proliferation.
While we demonstrate here strikingly low expression of
Hsd11b1 in both alpha and beta cells, there are apparently
contradictory reports in the literature concerning the expression
of this gene in beta cells and islets. Schmid et al. (2011) reported
HSD11B1 expression at the protein level throughout rat islets
and in INS-1 insulinoma cells, although this finding is sharply
refuted in a commentary by Liu et al. (2011) who question the
specificity of the antibody used. These authors also refer to their
previous paper (Chowdhury et al., 2015) reporting HSD11B1
expression in glucagon-positive cells of wild-type mouse islets
by immunofluorescence, and in islets by Western (immuno-
) blotting. There are further reports of HSD11B1 detection in
mouse islets after treatment with high-fat diet (Turban et al.,
2012) or in ob/ob mice (Davani et al., 2000). It is difficult to
reconcile these reports with the very low levels detected here in
both purified alpha and beta cells by RNA-Seq. Firstly, there are
clearly questions over the specificity of some of the antibodies
used in the previous studies. Secondly, we do detect substantially
higher expression in islets than in purified alpha or beta cells,
and previous use of qPCR and Western blotting were mainly
performed on isolated islets rather than purified cells. Our
results suggest that the Hsd11b1 expression detected in whole
islets comes almost exclusively from islet cell types other than
alpha and beta cells. Of course, since RNA-Seq measures the
transcript level it is possible that is does not accurately reflect the
protein level. However, it is difficult to envisage how such a large
discrepancy could occur. Finally, the cells used for the RNA-Seq
analysis were all from mice on normal diet, and it is possible that
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Hsd11b1 expression is induced under certain conditions such as
high-fat diet.
Interestingly, HSD11B1 levels were undetectable in 4/7
purified human beta cell preparations sampled by Blodgett
et al. (2015) and at <1 RPKM in the remaining three samples.
HSD11B1 mRNA was also absent in 2/7 purified human alpha cell
samples, and at around 1 RPKM in the other five. The latter data
indicate that the enzyme is also likely to be disallowed in both
human beta and alpha cells, as well as in rodent cells. In each
species this presumably provides a mechanism for “protecting”
these cell types from the effects of 11-DHC, or ensuring that
the actions of the precursor on the secretory function of these
cells (Davani et al., 2000) is via the presence of this enzyme in
neighboring islet cell types, as discussed above.
Mgll encodes monoglyceride lipase which is responsible for
the unregulated hydrolysis of monoacylglycerides (MAG) in
adipocytes and other tissues (Karlsson et al., 1997). Two other
lipases, Adipose Triglyceride Lipase (ATGL) and Hormone
Sensitive Lipase (HSL/LIPE) are both expressed in beta cells and
have been proposed to stimulate insulin secretion through the
production of lipid-derived coupling factors including MAG (Fex
et al., 2009; Attané et al., 2016). By degrading this MAG, it is
likely that expression of MGLL would remove this coupling factor
and decrease insulin secretion. Interestingly, both Mgll and Lipe
are dysregulated in beta cells null for PGC-1α/β. Knockout of
these PPARγ co-activators impairs fatty-acid potentiated insulin
secretion and was accompanied by down-regulation of Lipe
and up-regulation of Mgll. It is tempting to speculate that
maintained expression of Atgl and Lipe, along with suppression
of Mgll are necessary to allow MAG to act as a coupling
factor. It is interesting to note that overexpression of Acot7,
another disallowed gene involved in lipid metabolism, impairs
glucose-stimulated insulin secretion, although this appeared to be
through increased ATP consumption rather than decreased MAG
levels (Martinez-Sanchez et al., 2016).
Expression of PGC-1α is reduced in the islets from subjects
with type 2 diabetes (Ling et al., 2008), and this is paralleled by
a significant increase in Mgll expression in islets from diabetic
subjects (Table 1). Although it is unclear whether there is a direct
link between PGC-1α and Mgll expression, the dysregulation of
lipid metabolism associated with these changes could contribute
to the impaired beta cell function in type 2 diabetes.
Numerous studies have reported the pro-proliferative role
of IGF-1 on beta cells (reviewed in Stewart et al., 2015), and
exogenous IGF-1 treatment has been shown to increase beta
cell proliferation (Sieradzki et al., 1988). However, the effects
of locally produced IGF-1 may differ from those stimulated by
raised circulating levels of the growth factor. Beta cell-specific
overexpression of IGF-1 increased the survival and proliferation
of beta cells after challenge with multiple low dose streptozotocin-
treatment (George et al., 2002). Since this overexpression had
little effect on systemic serum levels of IGF-1 it presumably acted
in an autocrine/paracrine manner.
The action of IGF-1 is modulated by a family of IGF binding
proteins which regulate its bioavailability. Igfbp4 is strongly
disallowed in beta cells, and Igfbp2 is also within the top
50 disallowed genes for both alpha and beta cells. IGFBP4
is generally considered to have a negative regulatory role on
IGF-1, for example, both IGFBP4 and IGFBP2 were found
to be down-regulated through promoter hypermethylation in
lung carcinomas (Sato et al., 2006). In addition to binding
to IGF-1, thus preventing it binding to IGF receptors,
IGFBP4 has also been reported to act independently of
IGF (reviewed in Durai et al., 2006). However, there is
growing evidence that IGFBP4 may differentially regulate
proliferation in different contexts. Transfecting primary renal
cancer cell lines with IGFBP4 increased proliferation, invasion,
and motility, whereas knocking down the gene in metastatic
renal cancer cell lines decreased proliferation (Ueno et al.,
2011).
The complexity of its varying roles in other tissues makes it
difficult to predict what the effect of Igfbp4 overexpression in
islets would be. It also makes it difficult to suggest an adaptive
reason for its relative down-regulation in beta cells, and how this
might interact with the disallowance of Igf1. It is notable that
increased expression of both IGF1 and IGFBP4 in islets show
some association with type 2 diabetes (Table 1). Of the top 20
beta cell disallowed genes, IGF1 showed the strongest association
with diabetes status (p = 0.0185), whereas the association with
increased IGFBP4 was less strong (p = 0.0786). Future studies,
in which Igfbp1 is selectively over-expressed in beta cells, will be
needed to solve this conundrum.
Yap1 is a potent driver of cell growth via the Hippo pathway
(Hansen et al., 2015). Interestingly, a survey of human adult alpha
and beta cell expression data reveals levels of∼1 RPKM for YAP1
in both cell types, albeit with slightly lower levels in beta cells
(Blodgett et al., 2015). Nonetheless, in mouse cells, we found that
Yap1 and Pdgfrawere selectively repressed in beta cells, consistent
with a lower proliferative capacity of these cells relative to alpha
cells.
We therefore suspect that its suppression in beta cells
provides a mechanism to inhibit beta cell expansion, and hence
fatal hypoglycaemia. The absence of Yap1, Igf1 and potentially
Igfbp4 may also contribute to the low proliferative index of
beta cells in rodents but, more particularly in man, when cell
division is barely detectable after the age of ∼21 (Cnop et al.,
2010). Moreover, this, alongside the absence of Pdgfra (see
above) may equally restrict compensatory beta cell growth in
times of metabolic need including insulin resistance provoked
by diet, aging or pregnancy. Thus, mechanisms designed to
increase the expression or these receptors, or to engage their
downstream signaling pathways, may provide new approaches
toward regeneration of beta cell mass in type 2 diabetes.
Developmental Regulation of Expression
It is interesting to investigate at what stage in the developing
islet expression of these genes is down-regulated relative to
other tissues. It has previously been reported in developing rat
islets that Ldha and Slc16a1 expression peaked at post-natal
day 1 before reducing to near adult levels by P21 (Thorrez
et al., 2011). The current investigation of purified insulin-
positive cells from mice at stages E18 – P21 did not reveal
consistent down-regulation of disallowed genes during this
period (Figure 5A). Most of the beta cell disallowed genes
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exhibited low expression (<5 RPKM) by E18 and showed little
clear change during the post-natal period. One exception was
Gas1 which did show considerable down-regulation between
E18 and P7. However, this pattern did not extend across the
disallowed genes investigated. One possible explanation for
these differing results is that Thorrez et al. (2011) measured
expression in whole islets versus the purified insulin-positive cells
reported here. It is therefore possible that the down-regulation
observed in whole islets represents increases in the proportion
of beta (and other endocrine) cells in the developing islet,
whilst the expression of disallowed genes within these remains
unchanged during this period, as demonstrated experimentally
here.
CONCLUSION
The present report provides several novel insights. Notably,
we identify a novel member of the beta cell disallowed group,
Hsd11b1. Secondly, we reveal that assumptions as to the
expression of established members of the family, Yap1 and
Igf4bp1, as being disallowed in the alpha as well as the beta
cell, were misplaced. We further identify a module of 50 genes,
including Yap1, which are selectively down-regulated in beta
but not alpha cells. Our findings may provide the basis of new
approaches toward improving beta cell identity and function in
type 2 diabetes.
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